Henlius Reports NDA for its PD-L1 Inhibitor Accepted for China Review
April 22, 2021 at 05:08 AM EDT
Shanghai Henlius Biotech said the NDA for its novel anti-PD-L1 candidate has been accepted for review by China 's NMPA. Serplulimab injection (HLX10) was tested in patients with unresectable or metastatic microsatellite instability-high (MSI-H) solid tumors who did not respond to the standard therapy. It has the potential to be the first anti-PD-1 mAb approved for MSI-H solid tumors in China , the company said. So far, Henlius, an affiliate of Fosun Pharma, has launched three biosimilars in China . More details.... Stock Symbols: (HK:2696) (SHA: 600196; HK: 02196) Share this with colleagues: // //